Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products

Gene and cell therapy research recently reached a fundamental milestone toward the goal to deliver new medicines for orphan diseases. In 2016, the European Commission granted market approval to GlaxoSmithKline (GSK) for ex vivo hematopoietic stem cell (HSC) gene therapy for the treatment of adenosin...

Descripción completa

Detalles Bibliográficos
Autores principales: Aiuti, Alessandro, Roncarolo, Maria Grazia, Naldini, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452047/
https://www.ncbi.nlm.nih.gov/pubmed/28396566
http://dx.doi.org/10.15252/emmm.201707573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452047/
https://www.ncbi.nlm.nih.gov/pubmed/28396566
http://dx.doi.org/10.15252/emmm.201707573

Ejemplares similares